A case based understanding in co-development deal
In a Co-Development Agreement the intellectual property is typically licensed by the licensor to the alliance partner, and as well, the two... Read More
RIBOMIC – AJU Pharma licensing deal for RBM-007 in age-related macular degeneration
Posted on20 Mar 2020
Comments0
RBOMIC has finalized the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company. This deal is for RBM-007 licensing agreement for... Read More
Insight on Hikma and Glenmark’s Exclusive Licensing Agreement for Commercialising Ryaltris Nasal Spray in the US
Posted on28 Feb 2020
Tagsdrug licensing, Glemark outlicensing, Glenmark, global pharma licensing deal, Hikma, inlicensing in pharma, Ryaltris
Comments0
Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company signed of an exclusive... Read More
Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
South Korean company Alteogen Inc. signed a nonexclusive global license agreement with a top 10 global pharmaceutical company for its recombinant human... Read More
Mitsubishi Tanabe Pharma, Daiichi Sankyo enters licensing agreement for ALS treatment agent edaravone in Brazil
Posted on18 Sep 2019
Comments0
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo announced that they have concluded a licensing agreement covering commercialization rights in Brazil for an... Read More
Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
Posted on12 Sep 2019
Comments0
Alexion Pharmaceuticals announced a license agreement with BridgeBio Pharma’s subsidiary Eidos Therapeutics. Per the terms of the deal, Alexion will obtain an... Read More
Calixar licensing agreement with Regeneron
Calixar SAS, a biotechnology company specialized in native membrane protein stabilization, has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals, Inc.... Read More
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Posted on02 May 2019
TagsBiosimilar, biosimilar deals, biosimilar of sandoz, drug licensing, EirGenix, sandoz, trastuzumab
Comments0
Sandoz, a Novartis division and a global leader in biosimilars, has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This... Read More
Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More